コンテンツへスキップ
Merck

Hospital-acquired influenza in an Australian sentinel surveillance system.

The Medical journal of Australia (2013-04-16)
Nenad Macesic, Tom C Kotsimbos, Paul Kelly, Allen C Cheng
要旨

To review cases of nosocomial influenza and compare the epidemiology, clinical characteristics and outcomes with community-acquired cases. Prospective case series of adults hospitalised with influenza during April - November of 2010 and 2011 using a hospital-based sentinel surveillance system. A nosocomial case was defined as polymerase chain reaction-confirmed influenza where symptom onset was more than 2 15s after admission or, if this was not known, where the date of the positive test was more than 7 15s after admission. Demographic, clinical and outcome measures for patients with nosocomial influenza compared with patients admitted with community-acquired influenza. In 2010-2011, 598 cases of influenza were detected, of which 26 (4.3%) were nosocomial. All patients with nosocomial influenza had chronic comorbidities, compared with 71.7% of patients (410/572) with community-acquired influenza (P = 0.001). Similar proportions of community-acquired (32.5%) and nosocomial (36.4%) cases occurred in patients vaccinated in the current season. Clinical findings at time of enrollment did not differ between the two groups, with similar rates of fever, cough, chest pain and dyspnoea. Compared with community-acquired cases, a higher proportion of patients with nosocomial influenza received neuraminidase inhibitors within 2 15s of symptom onset (38.5% v 15.9%; P = 0.003). Admission to intensive care took place in 21.3% and 23.1% of community-acquired and nosocomial cases, respectively. One death from nosocomial influenza occurred in a patient with end-stage respiratory disease. Nosocomial influenza is uncommon but may be associated with severe disease. It may be partially preventable as patients frequently have comorbidities for which influenza vaccination is recommended. Patients, particularly those at high risk of complications, and their contacts (including health care workers) should be vaccinated to prevent severe disease.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ノイラミニダーゼ Clostridium perfringens(ウェルシュ菌)由来, Suitable for manufacturing of diagnostic kits and reagents, Type V, lyophilized powder
Sigma-Aldrich
ノイラミニダーゼ コレラ菌由来, Type III, buffered aqueous solution, 0.2 μm filtered, 1-5 units/mg protein (Lowry, using NAN-lactose)
Sigma-Aldrich
ノイラミニダーゼ Clostridium perfringens(ウェルシュ菌)由来, Type X, lyophilized powder, ≥50 units/mg protein (using 4MU-NANA)
Sigma-Aldrich
ノイラミニダーゼ コレラ菌由来, Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)
Sigma-Aldrich
α(2→3,6,8,9)ノイラミニダーゼ Arthrobacter ureafaciens由来, recombinant, expressed in E. coli, buffered aqueous solution
Sigma-Aldrich
α(2→3,6,8,9)ノイラミニダーゼ Arthrobacter ureafaciens由来, Proteomics Grade, suitable for MALDI-TOF MS
Sigma-Aldrich
ノイラミニダーゼ Clostridium perfringens(ウェルシュ菌)由来, Type VI, lyophilized powder, 6-15 units/mg protein (using 4MU-NANA), 2-10 units/mg protein (mucin)
Sigma-Aldrich
ノイラミニダーゼ Clostridium perfringens(ウェルシュ菌)由来, Type VIII, lyophilized powder, 10-20 units/mg protein (using 4MU-NANA), 3.5-8.0 units/mg protein (mucin)
Sigma-Aldrich
α(2→3,6)ノイラミニダーゼ Clostridium perfringens(ウェルシュ菌)由来, recombinant, expressed in E. coli, buffered aqueous solution, ≥250 units/mg protein
Sigma-Aldrich
α(2→3)ノイラミニダーゼ 肺炎レンサ球菌由来, buffered aqueous solution
Sigma-Aldrich
ノイラミニダーゼアガロース Clostridium perfringens(ウェルシュ菌)由来, Type VI-A, ammonium sulfate suspension